Last reviewed · How we verify
optimized medical management
optimized medical management is a Small molecule drug developed by University Hospital, Lille. It is currently FDA-approved.
Optimized medical management is a treatment approach rather than a discrete drug, involving coordinated clinical interventions tailored to individual patient needs.
Left Bundle Branch Pacing combined with Guideline-Directed Medical Therapy (LBBP+GDMT) is being studied as a potential treatment for non-ischemic heart failure and left bundle branch block. The effectiveness of LBBP+GDMT is being compared to usual care in clinical trials such as NCT05572957.
At a glance
| Generic name | optimized medical management |
|---|---|
| Sponsor | University Hospital, Lille |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This term refers to a comprehensive care strategy that optimizes existing therapeutic options, lifestyle modifications, and clinical monitoring rather than introducing a novel pharmacological agent. It is typically used in clinical practice to describe best-practice management protocols implemented at healthcare institutions.
Approved indications
Common side effects
Key clinical trials
- POP SINGER Pilot Study (NA)
- A Privacy-Preserving OCR-LLM System for Coronary Syndrome Subtyping From Admission HPI: Multicenter Validation in China and the US
- Effects of Preoperative Multidisciplinary Team Meetings for High-risk, Adult, Noncardiac Surgical Patients (NA)
- ReActiv8 Stimulation Therapy vs Optimal Medical Management: A Randomized Evaluation (NA)
- Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases (PHASE2)
- Research on Intraoperative Hypothermia Risk Prediction Model and Temperature Management Strategy for Elderly Patients During Surgery Based on Dynamic Incremental Training (NA)
- mHealth to Enhance & Sustain Drug Use Reduction of the QUIT BI in Primary Care (NA)
- Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- optimized medical management CI brief — competitive landscape report
- optimized medical management updates RSS · CI watch RSS
- University Hospital, Lille portfolio CI
Frequently asked questions about optimized medical management
What is optimized medical management?
How does optimized medical management work?
Who makes optimized medical management?
What development phase is optimized medical management in?
Related
- Manufacturer: University Hospital, Lille — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing